Saliu Jamiyu A
Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria.
Bioinform Biol Insights. 2024 Jul 30;18:11779322241262635. doi: 10.1177/11779322241262635. eCollection 2024.
Chagas Disease, caused by the parasite , remains a significant public health concern, particularly in Latin America. The current standard treatment for Chagas Disease, benznidazole, is associated with various side effects, necessitating the search for alternative therapeutic options. In this study, we aimed to identify potential therapeutics for Chagas Disease through a comprehensive computational analysis.
A library of compounds derived from was screened using a combination of pharmacophore modeling, structure-based screening, and quantitative structure-activity relationship (QSAR) analysis. The pharmacophore model facilitated the efficient screening of the compound library, while the structure-based screening identified hit compounds with promising inhibitory potential against the target enzyme, sterol-14-alpha demethylase.
The QSAR model predicted the bioactivity of the hit compounds, revealing one compound to exhibit superior activity compared to benznidazole. Evaluation of the physicochemical, pharmacokinetic, toxicity, and medicinal chemistry properties of the hit compounds indicated their drug-like characteristics, oral bioavailability, ease of synthesis, and reduced toxicity profiles.
Overall, our findings present a promising avenue for the discovery of novel therapeutics for Chagas Disease. The identified hit compounds possess favorable drug-like properties and demonstrate potent inhibitory effects against the target enzyme. Further in vitro and in vivo studies are warranted to validate their efficacy and safety profiles.
由该寄生虫引起的恰加斯病仍然是一个重大的公共卫生问题,尤其是在拉丁美洲。恰加斯病目前的标准治疗药物苯硝唑会产生各种副作用,因此需要寻找替代治疗方案。在本研究中,我们旨在通过全面的计算分析来确定恰加斯病的潜在治疗药物。
使用药效团建模、基于结构的筛选和定量构效关系(QSAR)分析相结合的方法,对源自[具体来源未给出]的化合物库进行筛选。药效团模型有助于高效筛选化合物库,而基于结构的筛选则识别出对目标酶甾醇-14-α脱甲基酶具有潜在抑制作用的命中化合物。
QSAR模型预测了命中化合物的生物活性,发现一种化合物的活性优于苯硝唑。对命中化合物的物理化学、药代动力学、毒性和药物化学性质的评估表明它们具有类药物特性、口服生物利用度、易于合成以及较低的毒性特征。
总体而言,我们的研究结果为发现恰加斯病的新型治疗药物提供了一条有前景的途径。所鉴定的命中化合物具有良好的类药物特性,并对目标酶表现出强大的抑制作用。有必要进一步进行体外和体内研究以验证它们的疗效和安全性。